Literature DB >> 15461582

Cloning, expression and characterization of a sialidase gene from Arthrobacter ureafaciens.

Søren Christensen1, Jan Egebjerg.   

Abstract

Sialidases have recently been used in the processing of clinically relevant asialoproteins. The Arthrobacter ureafaciens sialidase (EC 3.2.1.18) exhibits broad substrate specificity and is often used in such applications. We have employed an expression cloning strategy to isolate the A. ureafaciens sialidase. The clone encodes a 990-amino-acid 104 kDa open-reading-frame protein containing three domains: an N-terminal catalytic domain, a linker domain with an immunoglobulin-like fold and a C-terminal domain of unknown function. Expression in Escherichia coli indicates that the sialidase promoter was active in E. coli. Overexpression in E. coli resulted in several truncated forms. A 54 kDa truncated variant was generated, expressed and purified, and its feasibility for use in an erythropoietin desialylation process was demonstrated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15461582     DOI: 10.1042/BA20040144

Source DB:  PubMed          Journal:  Biotechnol Appl Biochem        ISSN: 0885-4513            Impact factor:   2.431


  5 in total

1.  Identifying selective inhibitors against the human cytosolic sialidase NEU2 by substrate specificity studies.

Authors:  Yanhong Li; Hongzhi Cao; Hai Yu; Yi Chen; Kam Lau; Jingyao Qu; Vireak Thon; Go Sugiarto; Xi Chen
Journal:  Mol Biosyst       Date:  2011-01-04

2.  Conformational characterization of nerve growth factor-β reveals that its regulatory pro-part domain stabilizes three loop regions in its mature part.

Authors:  Esben Trabjerg; Fredrik Kartberg; Søren Christensen; Kasper D Rand
Journal:  J Biol Chem       Date:  2017-08-10       Impact factor: 5.157

3.  Engineering host cell lines to reduce terminal sialylation of secreted antibodies.

Authors:  Michael F Naso; Susan H Tam; Bernard J Scallon; T Shantha Raju
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

4.  A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.

Authors:  Henning R Stennicke; Marianne Kjalke; Ditte M Karpf; Kristoffer W Balling; Peter B Johansen; Torben Elm; Kristine Øvlisen; Flemming Möller; Heidi L Holmberg; Charlotte N Gudme; Egon Persson; Ida Hilden; Hermann Pelzer; Henrik Rahbek-Nielsen; Christina Jespersgaard; Are Bogsnes; Anette A Pedersen; Anne K Kristensen; Bernd Peschke; Wendy Kappers; Frederik Rode; Lars Thim; Mikael Tranholm; Mirella Ezban; Eva H N Olsen; Søren E Bjørn
Journal:  Blood       Date:  2013-01-18       Impact factor: 22.113

5.  Targeted glycan degradation potentiates the anticancer immune response in vivo.

Authors:  Melissa A Gray; Michal A Stanczak; Natália R Mantuano; Han Xiao; Johan F A Pijnenborg; Stacy A Malaker; Caitlyn L Miller; Payton A Weidenbacher; Julia T Tanzo; Green Ahn; Elliot C Woods; Heinz Läubli; Carolyn R Bertozzi
Journal:  Nat Chem Biol       Date:  2020-08-17       Impact factor: 15.040

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.